Changes in microglia underlie depressive symptoms brought on by exposure to chronic stress, a new study reports.
MDMA shows promise for the treatment of post-traumatic stress disorder. Combining the use of Ecstasy with psychotherapy treatments resulted in a reduction of PTSD symptoms after just one session. 54% of the study participants no longer met the PTSD criteria after two sessions. Patients also reported improvements in depression symptoms.
Researchers have shown that infrared and Raman spectroscopy – coupled with statistical analysis – can be used to tell the difference between normal brain tissue and the different tumor types that may arise in this tissue, based on its individual biochemical-cell ‘fingerprint’.
Zolgensma, an FDA approved gene therapy, supplements the production of the SMN protein to improve motor neuron function in children with spinal muscular atrophy after just one dose.
Undetected and undocumented cases of COVID-19 were largely responsible for the rapid spread of the virus in China. 86% of all infections were undocumented before the January 23 Wuhan travel shutdown. Per person, the undocumented infections were half as contagious as documented infections but were the source of two-thirds of documented infections.
Researchers report the median time from exposure to symptoms for the COVID-19 virus is 5.1 days. 97.5% of people who develop symptoms of coronavirus will do so within 11.5 days of exposure. For every 10,000 people quarantined for 14 days, an estimated 101 would develop symptoms after release.
MW-151, a new drug that blocks 'bad' inflammation in the brain is about to be tested in a new human trial. Researchers believe the new drug could help stave off dementia.
Infectious disease experts report between 40% and 70% of adults could become infected with coronavirus during the outbreak. In a new interview, Dr. Lipsitch, head of Harvard's T.H. Chan School of Public Health's Center for Communicable Disease Dynamics, discusses the risks and spread potential of COVID-19, and addresses how the infection could impact children's' health.
An international research team revealed the atomic‐level structure of the human peptidase enzyme meprin β (beta).
EIDD-2801, a new antiviral drug, has the potential to treat coronavirus. A new study reveals the drug can prevent severe lung injury in mouse models and cultured human lung cells infected with COVID-19. The drug will soon be ready for human testing.